Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01985971 · ClinicalTrials.gov registry record · NA
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
A NA study of Brain Metastases From Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT01985971 is a NA study of Brain Metastases From Breast Cancer that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01985971, a NA study of Brain Metastases From Breast Cancer, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
To estimate the presence of hypoxia in individual lesions after radiotherapy in patients with brain metastases from breast cancer as identified by F18 EF5 PET/CT imaging.
Conditions Studied
Interventions
- RADIATION PET/CT Imaging
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-08-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01985971
The ClinicalTrials.gov registry entry for NCT01985971 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases From Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PET/CT Imaging is the first listed.
NCT01985971 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01985971 about?
NCT01985971 is a clinical study titled "F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer". To estimate the presence of hypoxia in individual lesions after radiotherapy in patients with brain metastases from breast cancer as identified by F18 EF5 PET/CT imaging.
What is the current status of trial NCT01985971?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2011-03. Estimated completion is 2016-08-19.
What conditions does trial NCT01985971 study?
This clinical trial studies the following conditions: Brain Metastases From Breast Cancer.
What interventions are being tested in trial NCT01985971?
The interventions under investigation include: PET/CT Imaging (RADIATION).
Who is sponsoring clinical trial NCT01985971?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01985971 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.